chloroacetaldehyde has been researched along with Neoplasms in 6 studies
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The peak concentration and area under the curve (AUC) were determined for the parent compound and the metabolites 4-hydroxyifosfamide and chloracetaldehyde in eight patients who received two cycles of ICE chemotherapy (ifosfamide 5 g/m(2) day 1, carboplatin 300 mg/m(2) day 1, etoposide 100 mg/m(2) days 1-3)." | 2.73 | Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients. ( Brüggemann, SK; Peters, SO; Pfäffle, S; Wagner, T, 2007) |
| "Ifosfamide and mesna were infused over 24 and 36 h, respectively, at equal daily doses; carboplatin was given after ifosfamide to a target plasma area under the curve of 4 mg x min x ml(-1)." | 2.69 | Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. ( Bolanowska-Higdon, W; Creaven, PJ; Meropol, NJ; Murphy, M; Pendyala, L; Perez, R; Schwartz, G; Zdanowicz, J, 2000) |
| " Independent of the route of ifosfamide application on day 1, the terminal half-life on day 3 (when the drug was given by the alternative route) was decreased in 6 out of the 12 patients, thus indicating self-induction of hepatic metabolism." | 2.67 | Metabolism and pharmacokinetics of oral and intravenous ifosfamide. ( Cerny, T; Küpfer, A; Kurowski, V; Wagner, T, 1991) |
| " After oral application, ifosfamide absorption proceeded rapidly, the oral bioavailability was 0." | 2.67 | Metabolism and pharmacokinetics of oral and intravenous ifosfamide. ( Cerny, T; Küpfer, A; Kurowski, V; Wagner, T, 1991) |
| "Since CPA and IFO are widely used anticancer drugs, their efficacy is limited not only by their toxicity but also due to occurring resistance." | 2.49 | [Classical oxazaphosphorines--metabolism and therapeutic properties--new implications]. ( Górska, A; Hładoń, B; Misiura, K; Sikorska, M; Sloderbach, A, 2013) |
| " Those results are in agreement with literature data reporting that intracellular CAA toxic concentrations range from 35 to 320 μM, after therapeutic ifosfamide dosing." | 1.43 | Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models. ( Bois, FY; Hamon, J; Leclerc, E, 2016) |
| " A pharmacokinetic (PK) model described the production of CAA by the hepatocytes and its transport to the renal cells." | 1.43 | Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models. ( Bois, FY; Hamon, J; Leclerc, E, 2016) |
| " The kinetics of the excretion were compared following short-term and continuous ifosfamide infusion at a dosage of 3 g/m2." | 1.30 | Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion. ( Blaschke, G; Boos, J; Hohenlöchter, B; Jürgens, H; Rossi, R; Silies, H, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sloderbach, A | 1 |
| Górska, A | 1 |
| Sikorska, M | 1 |
| Misiura, K | 1 |
| Hładoń, B | 1 |
| Leclerc, E | 1 |
| Hamon, J | 1 |
| Bois, FY | 1 |
| Brüggemann, SK | 1 |
| Pfäffle, S | 1 |
| Peters, SO | 1 |
| Wagner, T | 2 |
| Silies, H | 1 |
| Blaschke, G | 1 |
| Hohenlöchter, B | 1 |
| Rossi, R | 1 |
| Jürgens, H | 1 |
| Boos, J | 1 |
| Pendyala, L | 1 |
| Creaven, PJ | 1 |
| Schwartz, G | 1 |
| Meropol, NJ | 1 |
| Bolanowska-Higdon, W | 1 |
| Zdanowicz, J | 1 |
| Murphy, M | 1 |
| Perez, R | 1 |
| Kurowski, V | 1 |
| Cerny, T | 1 |
| Küpfer, A | 1 |
1 review available for chloroacetaldehyde and Neoplasms
| Article | Year |
|---|---|
[Classical oxazaphosphorines--metabolism and therapeutic properties--new implications].
Topics: Acetaldehyde; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents; Biotransformation; Cyclophosph | 2013 |
3 trials available for chloroacetaldehyde and Neoplasms
| Article | Year |
|---|---|
Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients.
Topics: Acetaldehyde; Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Dexamethasone | 2007 |
Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Cysteine; Dose-Response Relationship, Drug; Glutath | 2000 |
Metabolism and pharmacokinetics of oral and intravenous ifosfamide.
Topics: Acetaldehyde; Administration, Oral; Adult; Aged; Female; Humans; Ifosfamide; Infusions, Intravenous; | 1991 |
2 other studies available for chloroacetaldehyde and Neoplasms
| Article | Year |
|---|---|
Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models.
Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Bayes Theorem; Cells, Cultured; Hepatocytes; Ifosfa | 2016 |
Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Topics: Acetaldehyde; Acrolein; Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Female; Humans; | 1998 |